Clinical Trial Update: Limited-duration Teclistamab [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a limited-duration dosing regimen of teclistamab for multiple myeloma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• TECVAYLI (TECLISTAMAB-CQYV)

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Myeloma Multiple | Phase 2 | Status: RECRUITING